Advertisement

Topics

Arbutus, Alexion sign licensing deal for rare disease mRNA drug

05:17 EDT 20 Mar 2017 | SmartBrief

Arbutus Biopharma has entered a licensing deal involving the use of its lipid nanoparticle delivery technology to develop Ale -More

Original Article: Arbutus, Alexion sign licensing deal for rare disease mRNA drug

NEXT ARTICLE

More From BioPortfolio on "Arbutus, Alexion sign licensing deal for rare disease mRNA drug"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...